Vigencell Inc. (308080)
KRX SM KRX SM Primary Summary
Vigencell Inc. (308080) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vigencell Inc. ever had a stock split?
Vigencell Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | - ISIN |
| KR Country | 65 Employees | - Last Dividend | 8 Jun 2022 Last Split | - IPO Date |
Overview
ViGenCell Inc. is a biotechnology firm rooted in the field of immune cell therapy. The company has established itself as a pioneer in the development of innovative treatments aimed at combating cancer and other diseases through targeted cell therapy platforms. Founded in 1995, ViGenCell Inc. has its headquarters in Seoul, South Korea, illustrating its position as a key player in the biotech industry both locally and internationally. Through its commitment to research and development, ViGenCell Inc. seeks to improve patient outcomes by leveraging the power of the immune system to fight disease.
Products and Services
- ViTier
- ViRanger
- ViMedier
ViTier represents a cutting-edge T-cell therapy platform developed by ViGenCell Inc. This platform harnesses antigen-specific killer T cells, which are engineered to identify and eliminate cancer cells selectively. By targeting cancer cells with high precision, ViTier offers a promising approach to cancer treatment, reducing the impact on healthy cells and potentially improving patient recovery times and outcomes.
As another cornerstone of ViGenCell Inc.'s offerings, ViRanger is a T-cell gene therapy platform. It leverages innate killer T cells, which are genetically modified to seek out and destroy abnormal cells. This platform is designed to provide a broad-spectrum defense against various pathological conditions by eliminating cells that show signs of disease or malignancy, thereby offering a versatile approach to disease management and treatment.
ViMedier marks a significant advancement in immunosuppressive cell therapy. Utilizing the differentiation and expansion of cord blood-derived myeloid suppressor cells, this platform aims for universal application. It provides a novel solution for diseases characterized by an overactive immune response, by moderating immune function in a controlled manner. ViMedier’s approach holds promise for improving the quality of life for patients with autoimmune diseases and for enhancing outcomes in organ transplantation by reducing the risk of rejection.
